首页> 外文期刊>Journal of clinical psychopharmacology >Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic schizophrenia.
【24h】

Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic schizophrenia.

机译:中国慢性精神分裂症患者逐步停用长期抗胆碱能抗帕金森药物。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Previous antiparkinson drug withdrawal studies involving white subjects have yielded inconclusive findings, whereas there is a paucity of data concerning Asian patients. A double-blind, placebo-controlled, randomized trial using gradual withdrawal of antiparkinson medication was conducted to evaluate the need for maintenance antiparkinson therapy for clinically stable Chinese patients with chronic schizophrenia. Seventy-five schizophrenic subjects who had received a diagnosis according to DSM-IV who had been ill for at least 5 years and on antipsychotic and antiparkinson medication for a minimum of 2 years entered the study. After baseline assessment, 58 subjects were matched according to age, sex, age at onset, length of illness, dose and length of antipsychotic and antiparkinson medication, and the presence of various extrapyramidal side effects. Randomly assigned dose-reduction and control groups were formed consisting of 29 subjects each. Trihexyphenidyl (THP), the only oral antiparkinson drug used in the study, was reduced by 1 mg every 2 weeks, whereas other psychotropic medication remained unchanged. Monthly assessment was performed using the Brief Psychiatric Rating Scale, Hamilton Rating Scale for Depression, Abnormal Involuntary Movement Scale, Simpson-Angus Scale, Barnes Akathisia Rating Scale, and the Nursing Observation Scale for Inpatient Evaluation-30. Complete withdrawal of THP was possible in 25 (90%) of the 28 subjects who completed the study, whereas considerable dose reduction was achieved in the remaining 3 subjects. There were no significant differences between dose reduction and control groups on any of the rating scales at the completion of the study. Our results suggest that long-term prophylactic administration of antiparkinson medication is unnecessary in the treatment of the majority of Chinese patients with chronic schizophrenia because withdrawal was accomplished without adverse mental or motor effects.
机译:先前涉及白人受试者的抗帕金森药物戒断研究结果尚无定论,而有关亚洲患者的数据却很少。通过逐步停用抗帕金森药物进行了一项双盲,安慰剂对照的随机试验,以评估对临床稳定的中国慢性精神分裂症患者进行抗帕金森治疗的必要性。根据DSM-IV诊断为精神病的75名精神分裂症患者,他们至少病了5年,并且服用了抗精神病药和抗帕金森病药物至少2年才进入研究。基线评估后,根据年龄,性别,发病年龄,病程,抗精神病药和抗帕金森病药物的剂量和时间以及各种锥体束外副作用的存在,对58名受试者进行了匹配。随机分配剂量减少组和对照组,每组由29名受试者组成。该研究中使用的唯一口服抗帕金森药物三己基哌啶(THP)每2周减少1 mg,而其他精神药物保持不变。每月评估使用简明精神病评定量表,汉密尔顿抑郁量表,非自愿运动量表,辛普森-安格斯量表,Barnes Akathisia量表和住院患者护理观察量表-30。在完成研究的28位受试者中,有25位(90%)可以完全撤出THP,而在其余3位受试者中,THP的剂量明显减少。研究结束时,在任何等级量表上,减量剂量组和对照组之间均无显着差异。我们的研究结果表明,对于大多数中国慢性精神分裂症患者,不需要长期预防性给予抗帕金森药物,因为撤药是在没有不良精神或运动影响的情况下完成的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号